Search alternatives:
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
e decrease » _ decreased (Expand Search), _ decreases (Expand Search), a decreased (Expand Search)
a decrease » _ decreased (Expand Search), _ decreases (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
e decrease » _ decreased (Expand Search), _ decreases (Expand Search), a decreased (Expand Search)
a decrease » _ decreased (Expand Search), _ decreases (Expand Search)
-
1
-
2
-
3
-
4
The rate of lariat formation is decreased two-fold by isoginkgetin treatment.
Published 2014“…(<b>C</b>) Isoginkgetin treatment leads to a decreased rate of lariat formation (* indicates <i>p</i> = 0.02) without affecting exon ligation or excised lariat degradation (<i>p</i> = 0.22, 0.08), with calculations as in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0089673#pone-0089673-g001" target="_blank">Fig. 1</a>. …”
-
5
-
6
-
7
A decrease in cellular RNA increases the insolubility of TDP-43.
Published 2013“…The amount of RNA that binds to mtRNP2 was significantly decreased in comparison with wild-type TDP-43 (<i>p</i><0.001). …”
-
8
Genes and pathways decreased in 16E6/FN123 HFKs.
Published 2017“…Fold change shown is the average fold change over all 16E6 HFK cell lines in which that gene was decreased. …”
-
9
-
10
-
11
GO analysis of stage-salient genes in the order of decreasing significance (i.e, increasing p–value).
Published 2022“…<p>GO analysis of stage-salient genes in the order of decreasing significance (i.e, increasing p–value).</p>…”
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
VRK1 overexpression is seen in human breast cancer and is associated with decreased relapse-free survival.
Published 2018“…Data for cancer subtypes are shown in boxes numbered 1–11: 1: benign breast neoplasm (rank 6459, 1.4 fold-change, NS), 2: breast carcinoma (rank 833, 1.5 fold-change, p = 3.83x10<sup>-5</sup>), 3: breast phyllodes tumor (rank 512, 1.2 fold-change, p = 0.002), 4: ductal breast carcinoma in situ (rank 1969, 1.5 fold-change, p = 0.002), 5: invasive breast carcinoma (rank 1060, 1.6 fold-change, p = 1.28x10<sup>-5</sup>), 6: invasive ductal and invasive lobular breast carcinoma (rank 941, 1.5 fold-change, p = 6.76x10<sup>-22</sup>), 7: invasive ductal breast carcinoma (rank 613, 1.5-fold change, p = 2.71x10<sup>-71</sup>), 8: invasive lobular breast carcinoma (rank 947, 1.3 fold-change, p = 3.64x10<sup>-28</sup>), 9: medullary breast carcinoma (rank 400, 1.8 fold-change, p = 3.25x10<sup>-12</sup>), 10: mucinous breast carcinoma (rank 1932, 1.4 fold-change, p = 7.41x10<sup>-10</sup>) and 11: tubular breast carcinoma (rank 1253, 1.4 fold-change, p = 1.24x10<sup>-17</sup>). …”
-
20
<i>Dmxl2</i> knockdown in INS-1E cells decreases glucose-induced insulin release.
Published 2014“…(B) Seventy-two hours after the transfection of INS-1E cells with <i>Dmxl2-</i>siRNA, <i>Dmxl2</i> mRNA levels had decreased by 75% (error bars: SEM; from three independent experiments). …”